DIVI S LABORATORIES LTD vs Sandu Pharmaceuticals Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Sandu Pharmaceuticals Ltd (SANDUPHQ) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs SANDUPHQ on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability40
  • Growth20
  • Size & financial health30
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

SANDUPHQ takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.08
P/E ratio
23.91
10.62
P/B ratio
1.02
0.33%
Dividend yield
2.70%
₹96.73
EPS
₹1.60

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
4.13%
22.00%
Return on capital
5.47%
33.00%
EBITDA margin
4.11%
24.32%
Net margin
2.31%

Growth

DIVISLAB takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
1.03%
12.10%
Profit CAGR (3Y)
1.72%

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.42L Cr
Market cap
₹37 Cr
₹10,560 Cr
Revenue
₹67 Cr
₹2,568 Cr
Net profit
₹2 Cr
0.00
Debt / equity even
0.00
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Sandu Pharmaceuticals Ltd
  • + ["Company is almost debt free.", "Stock is trading at 0.85 times its book value", "Company's working capital requirements have reduced from 53.8 days to 42.0 days"]
  • ["The company has delivered a poor sales growth of 3.54% over past five years.", "Promoter holding is low: 37.8%", "Company has a low return on equity of 3.85% over last 3 years.", "Promoter holding has decreased over last 3 years: -14.6%"]
DIVI S LABORATORIES LTD full analysis Sandu Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.